{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:53:29Z","timestamp":1794668009313,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajpc.2026.101426","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:43Z","timestamp":1779217063000},"page":"101426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3034-080X","authenticated-orcid":false,"given":"Rosalynn","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadne Reyes","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alkholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vatsala","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshed A.","family":"Quyyumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Rasouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Neeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2026.101426_bib0001","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html, 2024 (accessed 11 December 2025)."},{"key":"10.1016\/j.ajpc.2026.101426_bib0002","unstructured":"International Diabetes Federation. Global: diabetes global report 200\u20132050. Diabetes Atlas. https:\/\/diabetesatlas.org\/data-by-location\/global\/, 2025 (accessed 11 December 2025)."},{"key":"10.1016\/j.ajpc.2026.101426_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2026.101426_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCULATIONAHA.117.028430","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: payer approvals, rejections, and patient characteristics for successful prescribing","volume":"136","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2026.101426_bib0006","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0007","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0008","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0009","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0011","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2026.101426_bib0012","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan","year":"2020","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ajpc.2026.101426_bib0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2026.101426_bib0014","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with ASCVD and type 2 diabetes: insights from the Department of Veterans Affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2026.101426_bib0015","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc21-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2026.101426_bib0016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2022.3839","article-title":"Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice","volume":"8","author":"Nanna","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2026.101426_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-pocket costs for SGLT-2 inhibitors in the United States","volume":"15","author":"Aggarwal","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ajpc.2026.101426_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.37765\/ajmc.2024.89510","article-title":"Out-of-pocket costs for diabetes medications in employer-sponsored health insurance plans","volume":"30","author":"Quach","year":"2024","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ajpc.2026.101426_bib0019","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.pcd.2022.10.005","article-title":"Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real world","volume":"16","author":"Franch-Nadal","year":"2022","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.ajpc.2026.101426_bib0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/jpm13050747","article-title":"Exposure-response analysis of the sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on kidney hemodynamics in patients with type 2 diabetes","volume":"13","author":"van der Hoek","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0021","doi-asserted-by":"crossref","first-page":"eabj9625","DOI":"10.1126\/scitranslmed.abj9625","article-title":"A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk","volume":"14","author":"Williams","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0022","first-page":"S49","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, 2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"129","author":"Goff Jr","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2026.101426_bib0023","article-title":"Clinical variation in the treatment practices for patients with type 2 diabetes: a cross-sectional patient simulation study among primary care physicians and cardiologists","volume":"12","author":"De Belen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2026.101426_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13098-023-01122-w","article-title":"Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial","volume":"15","author":"Peabody","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ajpc.2026.101426_bib0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpc.2026.101426_bib0026","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2337\/dc23-0602","article-title":"Prediction of cardiometabolic health through changes in plasma proteins with intentional weight loss in the DiRECT and DIADEM-I randomized clinical trials of type 2 diabetes remission","volume":"46","author":"Sattar","year":"2023","journal-title":"Diabetes Care"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:24:31Z","timestamp":1789039471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"alternative-id":["S2666667726000206"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101426","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101426"}}